NEW YORK (GenomeWeb) ― Abbott announced today that its pathogen detection platform, Iridica, has obtained CE marking and is now available in Europe and other countries that recognize the CE mark.

The diagnostic platform uses a combination of PCR and electrospray ionization mass spectrometry to amplify and detect pathogens directly from patient samples without the need for culture. It can currently distinguish over 1,000 bacteria, viruses, and fungi, according to a statement, allowing for unbiased screening of patient samples in less than six hours.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.